Trial Profile
A Safety, Tolerability and Pharmacokinetic Dose Escalation and Expansion, Phase I/Ib Study of AMC303 as Monotherapy in Patients With Advanced or Metastatic, Malignant Solid Tumour of Epithelial Origin
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2021
Price :
$35
*
At a glance
- Drugs AMC 303 (Primary)
- Indications Carcinoma; Cervical cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Biomarker; First in man
- Sponsors amcure
- 07 May 2021 Status changed from active, no longer recruiting to completed.
- 15 Jan 2021 Planned End Date changed from 1 Sep 2020 to 1 Feb 2021.
- 10 Apr 2020 Planned End Date changed from 1 Sep 2019 to 1 Sep 2020.